All News

cush.tkr_.jpg

TKR - One or Two at a Time?

d RheumNow

His would-be surgeon tried mightily to talk him out of a bilateral knee replacement. At 340 pounds, the patient's BMI -- above 43 -- was a significant contraindication. 

Read Article
bone%20dense.jpg (keep)

Older Men Less Likely to be Assessed and Treated for Osteoporosis

d Jack Cush, MD

A study from the University of Washington in Seattle find that men with osteoporosis were less likely to be assessed by dual-energy X-ray absorptiometry (DXA); vitamin D measurements and were less like to receive calcium/vitamin D and bisphosphonate prescriptions. 

Read Article
hip.THR_.jpg

Hip Replacements Lasting 25 Years

d Jack Cush, MD

Lancet reports that, based on a literature review and metanalysis, patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

Read Article
Review of IL-21 - made by follicular helper T & Th17 cells; promotes B cell maturation/function, mediated thru activation of the JAK/STAT, MAPK, PI3K pathways. IL-21 is increased in autoimmune patients - may be Rx target in RA, SLE, RA, T1D, PsA https://t.co/ld1Q3fHw9N

Links:

Dr. John Cush RheumNow ( View Tweet)

Review of 541,744 total knee replacement (TKR) in Australia (1999-2017) finds lower revision rates in RA vs. OA, but increased risk of infection in RA (esp. males) https://t.co/rIpSFWSNfY

Links:

Dr. John Cush RheumNow ( View Tweet)

Finnish population study of 4180 JIA patients shows JIA mortality not increased (0.6%) vs Nl population. Mmean age at death 20.3 yrs; Most common JIA cause was accidents, vs. suicide in controls. JIA pts had less substance abuse and depression https://t.co/9WiJJPxChR

Links:

Dr. John Cush RheumNow ( View Tweet)

Lancet study of 10166 chronic Hepatitis C patients shows treatment with direct-acting antivirals was associated with a 52% decrease in all-cause mortality (adjusted HR 0·48) and a 34% decrease in hepatocellular carcinoma (0·66) https://t.co/62HylUMUwE

Links:

Dr. John Cush RheumNow ( View Tweet)

Listen to the speakers from last weeks RWCS 2019 Podcast from Maui- https://t.co/hA1A0CHCz0

Links:

Dr. John Cush RheumNow ( View Tweet)

More than half (53%) of hospital deaths are from sepsis and sepsis is the most common immediate cause of death (35%) according to a medical record review from 6 academic centers https://t.co/Sp5rFTbg3m

Links:

Dr. John Cush RheumNow ( View Tweet)

"In order to solve a problem, you need to sell it first.....remarket your problem with a story that resonates." - Seth Godin  https://t.co/HHF9eMV7sk

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr Orrin Troum shows data on ANA negative pts. Should this include those with cytoplasmic staining? #RWCS2019 https://t.co/EDV882CQ9E
Dr. John Cush RheumNow ( View Tweet)
Dr Orrin Troum shows that TB Tspot is more sensitive than QFT in school of TB. But no specificity data. #RWCS2019 https://t.co/KJ2i0EKim3
Dr. John Cush RheumNow ( View Tweet)
The RheumNow Weekly Podcast is up! Info on SEAM-PsA, SEAM trial, MRI T2T, biologics & infection, contraceptive use, ANA negative lupus. View here>> https://t.co/tv2ANE0LAp or listen on iTunes or SoundClound https://t.co/uXZEI1jmkJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr Anne Stevens. Other arc options for localized scleroderma include tocilizumab and abatacept. #RWCS2019 https://t.co/AIfARTZ3CD
Dr. John Cush RheumNow ( View Tweet)
Dr Anne Stevens shows that CARRA pediatric rheums treat localized scleroderma with steroids and MTX #RWCS2019 https://t.co/h9s5Owz8J3
Dr. John Cush RheumNow ( View Tweet)
Dr Anne Stevens compare localized and diffuse pediatric scleroderma #RWCS2019 https://t.co/KJLGHlvqiE
Dr. John Cush RheumNow ( View Tweet)
FREEDOM trial 3,591 postmenop. women Rx w/ denosumab vs PBO x3 years - No difference in dental procedures (~45%), adjudicated osteonecrosis of jaw (13 cases) - risk was 0.68% vs. 0.05% w/ and withour invasive oral procedures. https://t.co/dxWuzEjUnk

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr Eric Ruderman shows that filgotinib (Jak inhibitor) maybe effect in ankylosing spondylitis. #RWCS2019 https://t.co/0km5vMHFpQ
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman shows data on the lack of effect with ustrkinumab in biological naive ankylosing spondylitis. #RWCS2019 https://t.co/Wqx7Us1Qrl
Dr. John Cush RheumNow ( View Tweet)
Dr Mark Genovese on Filgotinib (jak 1 inhibitor in development) showing no diff in responses despite falling 1, 2, 3 biologics #RWCS2019 https://t.co/dk7orkumEd
Dr. John Cush RheumNow ( View Tweet)
×